# A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

> **NCT02910635** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Abnormalities, Cardiovascular

## Interventions

- **DRUG:** Volanesorsen
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02910635
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-19
- **Primary completion:** 2016-12-20
- **Final completion:** 2016-12-20
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910635, "A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02910635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*